CRYSTALL

Genetic Foundation and Breeding Objectives

The 'Kristall' variety is a product of rigorous scientific development conducted by the Nikita Botanical Gardens (NBS-NNSC RAS). Unlike wild-harvested Helichrysum arenarium, the breeding program led by V. I. Mashanov and V. D. Rabotyagov was focused on standardizing the content of bioactive compounds. The commercial implementation of this variety allows for the production of raw materials with predictable levels of flavonoids and essential oils, which is a critical requirement for modern pharmaceutical manufacturing.

Technical Vegetation and Harvest Features

• Biological Stability: The variety is adapted to specific soil and climatic conditions, providing consistent growth cycles and reliable yield metrics.
• Morphological Uniformity: High plant uniformity enables efficient mechanical harvesting of the flower heads. The density of the inflorescences is optimized for rapid, consistent drying, which is essential for preserving volatile therapeutic components.
• Pharmacopoeial Standards: The selection process prioritized genotypes with the highest yield of extractive substances. This allows pharmaceutical manufacturers to reduce extraction costs while maintaining the specific medicinal potency of the final drug product.

Practical Application in Agropharmaceuticals

Utilizing 'Kristall' mitigates the risks associated with the inconsistency of wild-crafted materials. By transitioning to a controlled variety, agricultural producers can establish supply chains that meet strict GMP standards. The high concentration of active ingredients in each inflorescence makes this variety a core asset for the production of choleretic, anti-inflammatory, and hepatoprotective medications, ensuring both economic efficiency and therapeutic efficacy.